29 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.
Merck Sharp and Dohme Research Laboratories
Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Syntrix Biosystems
Synthesis and characterization of 5,6,7,8-tetrahydroquinoline C5a receptor antagonists.
Johnson & Johnson Prd
Inhibition of protein-protein association by small molecules: approaches and progress.
Pfizer
A nonpeptidic agonist ligand of the human C5a receptor: Synthesis, binding affinity optimization and functional characterization
TBA
Selective hexapeptide agonists and antagonists for human complement C3a receptor.
The University of Queensland
Identification of a new class of small molecule C5a receptor antagonists.
Wyeth Research
Design and optimization of aniline-substituted tetrahydroquinoline C5a receptor antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity.
Jerini
Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity.
The University of Queensland
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
University of Queensland
Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
University of Queensland
Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response.
University of Nebraska Medical Center
Chemical Approaches to Modulating Complement-Mediated Diseases.
The University of Queensland
Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.
Abbott Laboratories
Improvements in the minimum binding sequence of C5a: examination of His-67.
Abbott Laboratories
Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.
Abbott Laboratories
Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors
Mekanistic Therapeutics
Quinazolinones that inhibit the formation of tau oligomers and their method of use
Oligomerix